These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 8734631)

  • 1. Alprostadil for the treatment of erectile dysfunction.
    Kupecz D
    Nurse Pract; 1996 May; 21(5):143-5. PubMed ID: 8734631
    [No Abstract]   [Full Text] [Related]  

  • 2. [Erectile dysfunction].
    Lyngdorf P
    Ugeskr Laeger; 2002 Oct; 164(41):4779-83. PubMed ID: 12407881
    [No Abstract]   [Full Text] [Related]  

  • 3. [Drug treatment of sexual disorders in men].
    Slob AK; Gianotten WL
    Ned Tijdschr Geneeskd; 1996 Oct; 140(41):2029-32. PubMed ID: 8965939
    [No Abstract]   [Full Text] [Related]  

  • 4. The early use of transurethral alprostadil after radical prostatectomy potentially facilitates an earlier return of erectile function and successful sexual activity.
    Raina R; Pahlajani G; Agarwal A; Zippe CD
    BJU Int; 2007 Dec; 100(6):1317-21. PubMed ID: 17850385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Failure to attain stretched penile length after intracavernosal injection of a vasodilator agent is predictive of veno-occlusive dysfunction on penile duplex Doppler ultrasonography.
    Yafi FA; Libby RP; McCaslin IR; Sangkum P; Sikka SC; Hellstrom WJ
    Andrology; 2015 Sep; 3(5):919-23. PubMed ID: 26235901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erectile dysfunction--vasomotor actions of PGE1, its metabolites and other prostaglandins.
    Schrör K
    Adv Prostaglandin Thromboxane Leukot Res; 1995; 23():533-8. PubMed ID: 7732902
    [No Abstract]   [Full Text] [Related]  

  • 7. Enhancement of erectile responses to vasoactive drugs by a variable amplitude oscillation device.
    Chun SS; Fenemore J; Heaton JP; Johnston B; Morales A
    Int J Impot Res; 1996 Dec; 8(4):221-5. PubMed ID: 8981171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Drugs for impotence].
    Lukkarinen O; Pelkonen R
    Duodecim; 1995; 111(8):771-6. PubMed ID: 8681837
    [No Abstract]   [Full Text] [Related]  

  • 9. Intracavernous injection of alprostadil for erectile dysfunction.
    Med Lett Drugs Ther; 1995 Sep; 37(958):83-4. PubMed ID: 7674992
    [No Abstract]   [Full Text] [Related]  

  • 10. Erectile response to transurethral alprostadil, prazosin and alprostadil-prazosin combinations.
    Peterson CA; Bennett AH; Hellstrom WJ; Kaiser FE; Morley JE; Nemo KJ; Padma-Nathan H; Place VA; Prendergast JJ; Tam PY; Tanagho EA; Todd LK; Varady JC; Gesundheit N
    J Urol; 1998 May; 159(5):1523-7; discussion 1527-8. PubMed ID: 9554347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of sildenafil for safe improvement of erectile function and quality of life in men with New York Heart Association classes II and III congestive heart failure: a prospective, placebo-controlled, double-blind crossover trial.
    Webster LJ; Michelakis ED; Davis T; Archer SL
    Arch Intern Med; 2004 Mar; 164(5):514-20. PubMed ID: 15006828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The long-term safety of alprostadil (prostaglandin-E1) in patients with erectile dysfunction. The European Alprostadil Study Group.
    Br J Urol; 1998 Oct; 82(4):538-43. PubMed ID: 9806184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Symposium on Edex (alprostadil) in the diagnosis and treatment of erectile dysfunction].
    Borisov VV
    Urol Nefrol (Mosk); 1995; (6):53. PubMed ID: 8686130
    [No Abstract]   [Full Text] [Related]  

  • 14. Experience with intracavernous PGE-1 in the treatment of erectile dysfunction: dose considerations and efficacy.
    Ismail M; Abbott L; Hirsch IH
    Int J Impot Res; 1997 Mar; 9(1):39-42. PubMed ID: 9138057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy, safety and tolerability of intracavernous PNU-83757 for the treatment of erectile dysfunction.
    Vick RN; Benevides M; Patel M; Parivar K; Linnet O; Carson CC
    J Urol; 2002 Jun; 167(6):2618-23. PubMed ID: 11992097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A positive pharmacological erection test does not rule out arteriogenic erectile dysfunction.
    Cormio L; Nisén H; Selvaggi FP; Ruutu M
    J Urol; 1996 Nov; 156(5):1628-30. PubMed ID: 8863555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of linsidomine chlorhydrate, a direct nitric oxide donor, in the treatment of human erectile dysfunction: results of a double-blind cross over trial.
    Wegner HE; Knispel HH; Klän R; Miller K
    Int J Impot Res; 1995 Dec; 7(4):233-7. PubMed ID: 8770666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Intraurethrally applicated alprostadil for the treatment of organic erectile dysfunction in practice: a multicenter clinical monitoring study (noninterventional investigation)].
    Potempal AJ; Potempa DM; Görlich HD; Stolpmann RM
    Arzneimittelforschung; 2007; 57(6):299-308. PubMed ID: 17688074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prostaglandin E1 (PGE1) in diagnosis and long-term therapy of erectile dysfunction].
    Derouet H; Weirauch A; Bewermeier H
    Urologe A; 1996 Jan; 35(1):62-7. PubMed ID: 8851852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The penis as a vascular organ. The importance of corporal smooth muscle tone in the control of erection.
    Christ GJ
    Urol Clin North Am; 1995 Nov; 22(4):727-45. PubMed ID: 7483125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.